Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221455 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL6900506 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL25252134 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL2182699 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL6923340 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL7703626 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL9998357 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL21814404 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL6897847 | 0.79 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1MAPTHPGD | |
| SCHEMBL23748824 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPK1L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106595-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2022-04-07 | — | — | US | disclosed |
| EP-3887520-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020109792-A1 | ANTIBACTERIAL ANTISENSE AGENTS | Pedanius Therapeutics Limited (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106595-A1 | ANTIBACTERIAL ANTISENSE AGENTS | SLC47A1, SLC47A2, ZFR | ALDH1A1 4038/4885MAPK1 3559/4885L3MBTL1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.